SEC Form 4 · accession 0000899243-17-022447
BIODELIVERY SCIENCES INTERNATIONAL INC · BDSI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark A Sirgo
Officer — President and CEO · Director
Period of report
Sep 14, 2017
Accepted (ET)
Sep 22, 2017 · 5:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001103021
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 14, 2017 | S | 50,000 | $2.95 | D | 1,509,262 | D | |
| Common Stock | Sep 15, 2017 | M | 45,421 | $1.78 | A | 1,554,683 | D | |
| Common StockF2 | Sep 15, 2017 | M | 33,026 | $1.96 | A | 1,587,709 | D | |
| Common Stock | Sep 15, 2017 | S | 54,833 | $2.90 | D | 1,532,876 | D | |
| Common Stock | Sep 18, 2017 | S | 6,000 | $2.85 | D | 1,526,876 | D | |
| Common StockF3 | Sep 19, 2017 | M | 13,661 | $2.01 | A | 1,540,537 | D | |
| Common Stock | Sep 19, 2017 | S | 24,516 | $2.75 | D | 1,516,022 | D | |
| Common Stock | Sep 20, 2017 | M | 25,000 | $2.26 | A | 1,541,022 | D | |
| Common StockF4 | Sep 20, 2017 | M | 34,265 | $2.43 | A | 1,575,286 | D | |
| Common StockF5 | Sep 20, 2017 | S | 65,405 | $2.75 | D | 1,509,881 | D | |
| Common Stock | Sep 21, 2017 | S | 619 | $2.75 | D | 1,509,262 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options | $1.78 | Sep 15, 2017 | M | 45,421 | D | Feb 9, 2013 | Feb 9, 2022 | Common Stock | 45,421 | 0 | D |
| OptionsF2 | $1.96 | Sep 15, 2017 | M | 33,026 | D | Feb 15, 2013 | Feb 15, 2022 | Common Stock | 33,026 | 0 | D |
| OptionsF3 | $2.01 | Sep 19, 2017 | M | 13,661 | D | Jul 24, 2009 | Jul 24, 2018 | Common Stock | 6,902 | 0 | D |
| Options | $2.26 | Sep 20, 2017 | M | 25,000 | D | Jul 21, 2011 | Jul 21, 2020 | Common Stock | 25,000 | 0 | D |
| OptionsF4 | $2.43 | Sep 20, 2017 | M | 34,265 | D | Jul 21, 2011 | Jul 21, 2020 | Common Stock | 34,265 | 0 | D |
Explanation of responses
- F1On September 14, 2017, the Reporting Person sold an aggregate of 50,000 shares of the Issuer's Common Stock at a weighted average price of $2.95 per share. The highest sale price for the Common Stock was $2.98 per share and the lowest sale price was $2.90 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2The options exercised were acquired from September 15, 2017 to September 19, 2017.
- F3The options exercised were acquired from September 19, 2017 to September 20, 2017.
- F4The options exercised were acquired from September 20, 2017 to September 21, 2017.
- F5On September 20, 2017, the Reporting Person sold an aggregate of 65,405 shares of the Issuer's Common Stock at a weighted average price of $2.75 per share. The highest sale price for the Common Stock was $2.78 per share and the lowest sale price was $2.75 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Remarks
The Form 4 was due on September 18, 2017 but filed on September 22, 2017 to accommodate multiple connected transactions over several days all on one concise Form 4.